WO2023164179A1 - Benzothia(dia)zepine compounds for treatment of hbv and hdv - Google Patents

Abstract

The present disclosure provides, in part, benzothia(dia) zepine compounds of formula II and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.

Description

BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit of U.S. Provisional Application No.63/314,104, filed February 25, 2022, the contents of which are hereby incorporated by reference. BACKGROUND [0002] Hepatitis B (HBV) causes viral hepatitis that can further lead to chronic liver disease and increase the risk of liver cirrhosis and liver cancer (hepatocellular carcinoma). Worldwide, about 2 billion people have been infected with HBV, around 360 million people are chronically infected, and every year HBV infection causes more than one half million deaths. HBV can be spread by body fluids: from mother to child, by sex, and via blood products. Children born to HBV-positive mothers may also be infected, unless vaccinated at birth. [0003] The hepatitis virus particle is composed of a lipid envelope studded with surface protein (HBsAg) that surrounds the viral core. The core is composed of a protein shell, or capsid, built of 120 core protein (Cp) dimers, which in turn contains the relaxed circular DNA (rcDNA) viral genome as well as viral and host proteins. In an infected cell, the genome is found as a covalently closed circular DNA (cccDNA) in the host cell nucleus. The cccDNA is the template for viral RNAs and thus viral proteins. In the cytoplasm, Cp assembles around a complex of full-length viral RNA (the so-called pregenomic RNA or pgRNA and viral polymerase (P). After assembly, P reverse transcribes the pgRNA to rcDNA within the confines of the capsid to generate the DNA-filled viral core. [0004] At present, chronic HBV is primarily treated with nucleos(t)ide analogs (e.g., entecavir) that suppress the virus while the patient remains on treatment, but do not eliminate the infection, even after many years of treatment. Once a patient starts taking nucleos(t)ide analogs, most must continue taking them or risk the possibility of a life-threatening immune response due to viral rebound. Further, nucleotide therapy may lead to the emergence of antiviral drug resistance. [0005] The only FDA approved alternative to nucleos(t)ide analogs is treatment with interferon α or pegylated interferon α. Unfortunately, the adverse event incidence and profile of interferon α can result in poor tolerability, and many patients are unable to complete therapy. Moreover, only a small percentage of patients are considered appropriate for interferon therapy, as only a small subset of patients is likely to have a sustained clinical response to a course of interferon therapy. As a result, interferon-based therapies are used in only a small percentage of all diagnosed patients who elect treatment. [0006] Thus, current HBV treatments can range from palliative to watchful waiting. Nucleotide analogs suppress virus production, treating the symptom, but leave the infection intact. Interferon α has severe side effects and less tolerability among patients and is successful as a finite treatment strategy in only a small minority of patients. There is a clear on-going need for more effective treatments for HBV infections. [0007] Another form of viral hepatitis is Hepatitis D virus (HDV), a defective RNA virus that causes chronic viral hepatitis and eventual cirrhosis. However, the HDV life cycle is dependent on the presence of HBsAg for assembly. Thus, in a small set of patients infected with HBV, HDV presents as coinfection with HBV. See for example, Sagnelli et al., Life (Basel).2021 Feb; 11(2): 169, Published online 2021 Feb 22. doi: 10.3390/life11020169, herein incorporated by reference with regard to such background teaching. For patients already infected with HBV, coinfection with HDV can further exacerbate the symptoms of HBV, increasing the likelihood of complications, rapid disease progression and/or death. Chronic HBV/HDV infection is also associated with the development of hepatocellular carcinoma (HCC). Like HBV, treatment options for HDV infection or HBV/HDV coinfection, are limited and include those used to treat HBV. Thus, there is a need for effective therapeutic options for the treatment of HDV infection or HBV/HDV coinfection. [0008] WO2021/110883, WO2021/110884, WO2021/110885, WO2021/110886, WO2021/110887, WO2020/161216, WO2020/161217 and WO2019/234077 relate to 1,5- benzothiazepine and 1,2,5-benzothiadiazepine derivatives described as bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The compounds are further described as being useful to in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases. [0009] LBAT functions as a cellular receptor for viral entry of the hepatitis B virus (HBV) and hepatitis D virus (HDV), which in turn is the major cause of liver disease and hepatocellular carcinoma. There is a need for additional bile acid modulating compounds that have an improved profile with respect to potency, selectivity and/or bioavailability. SUMMARY [0010] The present disclosure provides, in part, benzothia(dia)zepine compounds and pharmaceutical compositions thereof, useful for inhibition of HBV or HDV replication, inhibition of HBV or HDV viral entry, and methods of treating HBV infections, HDV infection or HBV/HDV coinfection. [0011] In one aspect, the disclosure provides a compound of Formula I:

[0012] or a pharmaceutically acceptable salt thereof, where the variables are described in the detailed description. [0013] In another aspect, the disclosure provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. [0014] In another aspect, the disclosure provides a method of treating an HBV infection in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. [0015] In another aspect, the disclosure provides a method of treating an HBV infection in a subject in need thereof, comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. DETAILED DESCRIPTION [0016] The features and other details of the disclosure will now be more particularly described. Before further description of the present disclosure, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. I. Definitions [0017] The term “alkenyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups include, but are not limited to, a straight or branched group of 2-6 carbon atoms, referred to herein as C_2-6alkenyl. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, and pentenyl, etc. [0018] The term “alkoxy” as used herein refers to a straight or branched alkyl group attached to oxygen (i.e., alkyl-O-). Exemplary alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 1-4 carbon atoms, referred to herein as C_1-6alkoxy and C_1-4alkoxy, respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, and isopropoxy, etc. [0019] The term “alkoxyalkyl” as used herein refers to an alkyl group substituted with an alkoxy group. Examples include, but are not limited to, CH₃CH₂OCH₂-, CH₃OCH₂CH₂- and CH₃OCH₂-, etc. [0020] The term “alkyl” as used herein refers to a saturated straight or branched hydrocarbon. Exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6 or 1-4 carbon atoms, referred to herein as C_1-6 alkyl and C_1-4 alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-butyl, 3-methyl-2-butyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4- methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1- butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl, etc. The term “alkylene” as used herein refers to a biradical alkyl group. [0021] The term “alkynyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6 carbon atoms, referred to herein as C_2-6alkynyl. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and methylpropynyl, etc. [0022] The term “carbonyl” as used herein refers to the biradical -C(O)-. [0023] The term “coinfection” as used herein refers to simultaneous infection of a host by more than one viral pathogen. [0024] The term “cyano” as used herein refers to the radical -CN. [0025] The term “cycloalkyl” as used herein refers to a saturated monocyclic hydrocarbon group of, for example, 3-7 carbons, referred to herein as C_3-7monocycloalkyl, or bicyclic hydrocarbon ring structure of, for example, 5-12 carbons, referred to herein as C_{5- 12}bicycloalkyl. For bicyclic cycloalkyl groups, the two rings may be attached through the same or different carbons. Exemplary monocycloalkyl groups include, but are not limited to, cycloheptyl, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl and cyclopropyl. Exemplary bicycloalkyl groups include, but are not limited to, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[4.5]decanyl, spiro[5.5]undecanyl, spiro[2.4]heptanyl, spiro[3.4]octanyl, spiro[4.4]nonanyl, spiro[2.3]hexanyl, spiro[3.3]heptanyl, decahydronaphthalene, octahydro- 1H-indene, bicyclo[4.2.0]octanyl, bicyclo[4.1.0]heptanyl, octahydropentalenyl, bicyclo[3.2.0]heptanyl, bicyclo[3.1.0]hexanyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, and bicyclo[1.1.1]pentanyl. [0026] The terms “halo” or “halogen” as used herein refer to F, Cl, Br or I. [0027] The term “haloalkyl” as used herein refers to an alkyl group substituted with one or more halogen atoms. For example, haloC_1-6alkyl refers to a straight or branched alkyl group of 1-6 carbon atoms substituted with one or more halogen atoms. Examples include, but are not limited to, -CH₂F, -CHCl₂, -CHF₂, -CF₃, CF₃CH₂-, CH₃CF₂-, CF₃CCl₂- and CF₃CF₂-. [0028] The term “haloalkoxy” as used herein refers to an alkoxy group substituted with one or more halogen atoms. Examples include, but are not limited to, CCl₃O-, CF₃O-, CHF₂O- CF₃CH₂O-, and CF₃CF₂O-. [0029] The terms “heteroaryl” as used herein refers to a 5-6 membered monocyclic aromatic group, referred to herein as monocyclo_5-6heteroaryl, or 8-12 membered bicyclic aromatic ring system, referred to herein as bicyclo_8-12heteroaryl, containing one to four independently selected heteroatoms, such as nitrogen, oxygen and sulfur. Where possible, the heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen. Examples of monocyclo_5-6heteroaryl groups include, but are not limited to, furanyl, thiophenyl (also referred to as thienyl), pyrrolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,2,4-triazolyl, pyridinyl (also referred to as pyridyl), pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl and tetrazolyl. Examples of bicyclo_8-12heteroaryl groups include, but are not limited to, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzo[c]thiophenyl, indolyl, isoindolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]oxazolyl, benzo[d]isothiazolyl, benzo[c]isothiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d]imidazolyl, benzo[d]imidazolyl, and benzo[d][1,2,3]triazolyl. [0030] The term “heterocycloalkyl” refers to a monocycloalkyl group, for example a C3- ₇monocycloalkyl, or a bicycloalkyl group, for example C_5-12bicycloalkyl, wherein 1-3 of the carbon atoms are replaced with independently selected heteroatoms, such as nitrogen, oxygen, and sulfur (including its oxidation states: S(O) and SO₂), herein referred to as mono_{3- 7}heterocycloalkyl and bi_5-12heterocycloalkyl, respectively. Examples of mono_{3- 7}heterocycloalkyl groups include, but are not limited to, aziridinyl, oxiranyl, thiiranyl 1,1- dioxide, oxetanyl, azetidinyl, thietanyl 1,1-dioxide, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydro-2H-pyranyl, morpholinyl, thiomorpholinyl, and piperazinyl. Examples of bi_5-12heterocycloalkyl groups include, but are not limited to, 1,4-dioxaspiro[4.5]decanyl and 1,5-dioxaspiro[5.5]undecanyl. [0031] The terms “hydroxy” and “hydroxyl” as used herein refers to the radical -OH. [0032] The term “hydroxyalkyl” as used herein refers to an alkyl group substituted with one or more hydroxy groups. Examples include, but are not limited to, HOCH₂-, HOCH₂CH₂-, CH₃CH(OH)CH₂- and HOCH₂CH(OH)CH₂-. [0033] The term “hydroxyalkoxy” as used herein refers to an alkoxy group substituted with one or more hydroxy groups. Examples include but are not limited to HOCH₂O-, HOCH₂CH₂O-, CH₃CH(OH)CH₂O- and HOCH₂CH(OH)CH₂O-. [0034] The term “R^aR^bNC_1-6 alkyl-,” as used herein refers to an alkyl group substituted with a R^aR^bN- group, as defined herein. Examples include but are not limited to NH₂CH₂-, NH(CH₃)CH₂-, N(CH₃)₂CH₂CH₂- and CH₃CH(NH₂)CH₂-. [0035] The term “R^aR^bNC_1-6alkoxy,” as used herein refers to an alkoxy group substituted with a R^aR^bN- groups, as defined herein. Examples include but are not limited to NH₂CH₂-, NH(CH₃)CH₂O-, N(CH₃)₂CH₂CH₂O-, and CH₃CH(NH₂)CH₂O-. [0036] The term “oxo” as used herein refers to the radical =O. [0037] As used herein, when a bicyclic ring is shown with a floating point of attachment and/or floating substituents, for example as in it signifies that the bicyclic

ring can be attached via a carbon atom on either ring, and that the substituents (e.g., the R³³ group(s)) can be independently attached to either or both rings. [0038] The terms “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds or pharmaceutical compositions of the disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, dogs, primates, and the like). The mammal treated in the methods of the disclosure is desirably a mammal in which treatment of HBV infection is desired. [0039] The term “modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism. [0040] The term “Pharmaceutically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards. [0041] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, fillers, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions. [0042] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable excipients. [0043] The term "pharmaceutically acceptable salt(s)" as used herein refers to salts of acidic or basic groups that may be present in compounds used in the compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt. [0044] The term “therapeutically effective amount” or “effective amount” as used herein refers to the amount of the subject compound that will elicit the biological or medical response of a tissue, system or animal, (e.g., mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician. The compounds or pharmaceutical compositions of the disclosure are administered in therapeutically effective amounts to treat a disease. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect. [0045] The term “treating” includes any effect, e.g., lessening, reducing, modulating, or eliminating, a viral infection, that results in the improvement of the disease. [0046] The compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers. The term “stereoisomers” when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “(-),” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. The present disclosure encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. [0047] The compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond. The symbol

denotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond. [0048] Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring. The arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers. Substituents around a carbocyclic or heterocyclic ring may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.” [0049] Individual enantiomers and diastereomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well-known methods, such as chiral-phase liquid chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art. Stereoselective syntheses encompass both enantiomeric and diastereoselective transformations and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009. [0050] The compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a single polymorph. In another embodiment, the compound is a mixture of polymorphs. In another embodiment, the compound is in a crystalline form. [0051] The disclosure also embraces isotopically labeled compounds of the disclosure which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl, respectively. For example, a compound of the disclosure may have one or more H atom replaced with deuterium. [0052] Certain isotopically-labeled disclosed compounds (e.g., those labeled with ³H and ¹⁴C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e., ¹⁴C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. [0053] The term “prodrug” refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, et al., Nature Reviews Drug Discovery 2008, 7, 255). II. Benzothia(dia)zepine Compounds [0054] In one aspect, the present disclosure provides a compound of Formula I

, or a pharmaceutically acceptable salt thereof, wherein: M is NR^x or CR^yR^z; R¹ is phenyl or monocyclo_5-6heteroaryl, wherein the phenyl or monocyclo_5-6heteroaryl is substituted with R^0a and optionally substituted with 1-3 substituents independently selected from the group consisting of cyano, halo, C_1-4alkyl and haloC_1-4alkyl; R^0a is -C(O)OH, -CR^1dR^1eC(O)OH, -C(O)OC_1-6alkyl, -CR^1dR^1e C(O)OC_1-6alkyl, - P(O)(OH)₂, -CR^1dR^1eP(O)(OH)₂, -S(O)₂OH, -CR^1dR^1eS(O)₂OH, or wherein R^1d

and R^1e are independently selected from the group consisting of hydrogen, F, Me and CN; or R^1d and R^1e or together with the carbon atom to which they are attached form a C_3- 4monocyloalkyl or mono3-4heterocycloalkyl group; R², R³ and R⁴ are independently selected from the group consisting of hydrogen, halogen, cyano, C_1-4 alkyl, C_3-6 cycloalkyl, C_1-4 alkoxy, C_3-6cycloalkyloxy, C_1-4alkylthio, C_{3- 6}cycloalkylthio, haloC_1-4alkyl, haloC_3-6cycloalkyl, haloC_1-4alkoxy, haloC_3-6hcycloalkyloxy, haloC_1-4alkylthio, haloC_3-6cycloalkylthio, amino, N-(C_1-4 alkyl)amino and N,N-di(C_{1- 4} alkyl)amino; R⁵ and R⁶ are independently selected from the group consisting of hydrogen, C_{1- 6}alkyl, C_1-6alkenyl, C_1-6alkynyl, haloC_1-6alkyl, haloC_1-6alkenyl, haloC_1-6alkynyl, C_{1- 3}alkoxyC_1-3alkyl, and C_3-6cycloalyl-C_1-4alkylene-; or R⁵ and R⁶ together with the carbon atom to which they are attached form a C3-7monocycloalkyl or C5-12bicycloalkyl, wherein the C3- ₇monocycloalkyl or C_5-12bicycloalkyl is optionally substituted with 1-6 substituents independently selected from the group consisting of halogen, CN, NO₂, OH, R^aR^bN-, C_{1- 4}alkyl and haloC_1-4alkyl; R⁸ is independently selected for each occurrence from the group consisting of halogen, OH, CN, NO₂, hydrazino, formyl, azido, silyl, siloxy, HOC(O)-, R^aR^bN-, R^aR^bNS(O)_q-, C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, haloC_1-6alkyl, hydroxyC_1-6alkyl-, R^aR^bNC_{1- 6}alkyl-, HOC(O)C_1-6alkyl-, R^aR^bNC_1-6alkylNR^c-, C_1-6alkylNR^aC_1-6alkylNR^c-, C_1-6alkoxy, haloC_1-6alkoxy, hydroxyC_1-6alkoxy-, R^aR^bNC_1-6alkoxy-, C_1-6alkoxyC_1-6alkyl-, haloC_{1- 6}alkoxyC_1-6alkyl-, R^aR^bNC(O)-, C_1-6alkylC(O)-, C_1-6alkoxyC(O)-, C_1-6alkylC(O)O-, C_{1- 6}alkylS(O)_q-, C_1-6alkylS(O)_qNR^c-, C_1-6alkylS(O)_qC_1-6alkyl-, C_1-6alkylS(O)_qNR^aC_1-6alkyl-, C_{3- 6}cycloalkylS(O)_qC_1-6alkyl-, C_1-6alkylC(O)C_1-6alkyl-, and C_1-6alkylC(O)OC_1-6alkyl-; Ra, Rb and Rc are independently selected for each occurrence from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl and C3-6 monocycloalkyl; Rx, Ry and Rz are independently selected from the group consisting of hydrogen, halo, CN, NO2, C1-4alkyl, and haloC1-4C1-4alkyl; q is independently selected for each occurrence from the group consisting of 0, 1 and 2; and r is 0, 1, 2, 3, 4 or 5. [0055] The following embodiments further describe a compound of Formula I, or a pharmaceutically acceptable salt thereof. It will be appreciated that all chemically allowable combinations of the embodiments described herein are envisioned as further embodiments of the invention. [0056] In certain embodiments, M is NR^x. [0057] In certain embodiments, M is NR^x, and R^x is H or CH₃. [0058] In certain embodiments, M is NR^x and R^x is CH₃. [0059] In certain embodiments, M is CR^yR^z , R^y is halo, and R^z is halo. [0060] In certain embodiments, M is CR^yR^z, R^y is hydrogen, and R^z is halo. [0061] In certain embodiments, R^0a is -C(O)OH, -C(O)OC_1-6alkyl or -S(O)₂OH, [0062] In certain embodiments, R¹ is a phenyl or monocyclo_5-6heteroaryl, wherein the phenyl or monocyclo_5-6heteroaryl is substituted with R^0a and optionally substituted with 1-3 substituents independently selected from the group consisting of cyano, halo, C_1-4alkyl and haloC_1-4alkyl. [0063] In certain embodiments, R¹ is a phenyl substituted with R^0a and optionally substituted with 1-3 substituents independently selected from the group consisting of cyano, halo, C_1-4alkyl and haloC_1-4alkyl. [0064] In certain embodiments, R¹ is a monocyclo_5-6heteroaryl substituted with R^0a and optionally substituted with 1-3 substituents independently selected from the group consisting of cyano, halo, C_1-4alkyl and haloC_1-4alkyl. [0065] In certain embodiments, R² is hydrogen. [0066] In certain embodiments, R³ is hydrogen. [0067] In certain embodiments, R² and R³ are hydrogen. [0068] In certain embodiments, R⁴ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl, cyclopropyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino and dimethylamino. [0069] In certain embodiments, R⁴ is methylthio. [0070] In certain embodiments, R⁵ and R⁶ are independently selected from the group consisting of hydrogen and C_1-6alkyl. [0071] In certain embodiments, R⁵ is C_1-6alkyl and R⁶ is hydrogen. [0072] In certain embodiments, R⁵ is C_3-4alkyl and R⁶ is hydrogen. [0073] In certain embodiments, R⁵ is n-butyl and R⁶ is hydrogen. [0074] In certain embodiments, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, C_1-6alkenyl, C_1-6alkynyl, haloC_1-6alkyl, haloC_1-6alkenyl, haloC_{1- 6}alkynyl, C_1-3alkoxyC_1-3alkyl, and C_3-6cycloalyl-C_1-6alkylene-; or R⁵ and R⁶ together with the carbon atom to which they are attached form a C_3-7monocycloalkyl or C_5-12bicycloalkyl, wherein the C_3-7monocycloalkyl or C_5-12bicycloalkyl is optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, CN, NO₂, OH, R^aR^bN-, C_1-4alkyl and haloC_1-4alkyl. [0075] In certain embodiments, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, C_1-6alkenyl, C_1-6alkynyl, haloC_1-6alkyl, haloC_1-6alkenyl, haloC_1- 6alkynyl, C_1-3alkoxyC_1-3alkyl, and C_3-6cycloalyl-C_1-4alkylene-. [0076] In certain embodiments, R⁵ is C_1-6alkenyl, C_1-6alkynyl, haloC_1-6alkyl, haloC_{1- 6}alkenyl, haloC_1-6alkynyl, C_1-3alkoxyC_1-3alkyl, or C_3-6cycloalyl-C_1-4alkylene-; and R⁶ is hydrogen. [0077] In certain embodiments, R⁵ and R⁶ together with the carbon atom to which they are attached form a C_3-7monocycloalkyl or C_5-12bicycloalkyl, wherein the C_3-7monocycloalkyl or

C_5-12bicycloalkyl is optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, CN, NO₂, OH, R^aR^bN-, C_1-4alkyl and haloC_1-4alkyl. [0078] In certain embodiments, R⁵ and R⁶ together with the carbon atom to which they are attached form a

wherein: R⁹ is independently selected for each occurrence from the group consisting of halogen, CN, NO₂, OH, R^aR^bN-, C_1-4alkyl and haloC_1-4alkyl; and s is selected from the group consisting of 0, 1, 2 and 3. [0079] In certain embodiments, s is 0. [0080] In another aspect, the present disclosure provides a compound of Formula II

Formula II , or a pharmaceutically acceptable salt thereof, wherein: M is NR^x or CR²R³; R^x is hydrogen or C_1-4alkyl; and R⁰ is -C(O)OH, -C(O)OC_1-4alkyl, or -S(O)₂OH; [0081] R¹ is phenyl or monocyclo_5-6heteroaryl, wherein the phenyl or monocyclo_{5- 6}heteroaryl is substituted with R⁰ and optionally substituted with 1-3 substituents independently selected from the group consisting of cyano, halo, C_1-4alkyl, haloC_1-4alkyl, C_{1- 4}alkoxy and C_1-4alkylthio; [0082] R² and R³ are independently selected from the group consisting of hydrogen, halo and methyl. [0083] R⁴ is independently selected from the group consisting of hydrogen, halo, cyano, C_{1- 4}alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio; and [0084] R⁵ is phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy, and C_{1- 4}alkylthio. [0085] The following embodiments further describe a compound of Formula II, or a pharmaceutically acceptable salt thereof. It will be appreciated that all chemically allowable combinations of the embodiments described herein are envisioned as further embodiments of the invention. [0086] In certain embodiments, M is NR^x. [0087] In certain embodiments, M is NH or NCH₃. [0088] In certain embodiments, R⁰ is -C(O)OH or -C(O)OC_1-4alkyl. [0089] In certain embodiments, R⁰ is C(O)OH. [0090] In certain embodiments, R¹ is phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio. [0091] In certain embodiments, R¹ is monocyclo_5-6heteroaryl optionally substituted with 1- 3 substituents independently selected from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio. [0092] In certain embodiments, R¹ is

[0093] R⁶ is independently selected for each occurrence from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio; R^6a is hydrogen or C_1-6alkyl; X is O or S; v is 0, 1, 2 or 3; w is 0, 1 or 2; and u is 0 or 1. [0094] In certain embodiments, R⁴ is fluoro, methyl or methylthio. [0095] In certain embodiments, R⁴ is methylthio. [0096] In certain embodiments, R⁵ is

III. Pharmaceutical Compositions and Kits [0097] In another aspect, the disclosure provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In particular, the present disclosure provides pharmaceutical compositions comprising compounds as disclosed herein formulated together with one or more pharmaceutically acceptable carriers. These formulations include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used. For example, disclosed compositions may be formulated as a unit dose, and/or may be formulated for oral or subcutaneous administration. [0098] In another aspect, the disclosure provides a pharmaceutical composition comprises a compound according to any combination of the Examples described herein, or a pharmaceutically acceptable salt and/or stereoisomer thereof. [0099] Exemplary pharmaceutical compositions of this disclosure may be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains one or more compounds of the disclosure, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non- toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease. [0100] For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the disclosure, or a non- toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. [0101] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. [0102] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. [0103] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof. [0104] Suspensions, in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. [0105] Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non- irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent. [0106] Dosage forms for transdermal administration of a subject composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. [0107] The ointments, pastes, creams and gels may contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. [0108] Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. [0109] Compositions and compounds of the present disclosure may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers may be used because they minimize exposing the agent to shear, which may result in degradation of the compounds contained in the subject compositions. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions. [0110] Pharmaceutical compositions of this disclosure suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically- acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. [0111] Examples of suitable aqueous and non-aqueous carriers which may be employed in the pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins. Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. [0112] In another aspect, the disclosure provides enteral pharmaceutical formulations including a disclosed compound and an enteric material; and a pharmaceutically acceptable carrier or excipient thereof. Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs. The small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is about 5.5, the pH of the jejunum is about 6.5 and the pH of the distal ileum is about 7.5. Accordingly, enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10.0. Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate- chlorotrimethylammonium ethyl acrylate copolymer, natural resins such as zein, shellac and copal collophorium, and several commercially available enteric dispersion systems (e. g. , Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric). The solubility of each of the above materials is either known or is readily determinable in vitro. The foregoing is a list of possible materials, but one of skill in the art with the benefit of the disclosure would recognize that it is not comprehensive and that there are other enteric materials that would meet the objectives of the present disclosure. [0113] Advantageously, the disclosure also provides kits for use by e.g., a consumer in need of HBV infection treatment. Such kits include a suitable dosage form such as those described above and instructions describing the method of using such dosage form tomediate, reduce or prevent HBV infection. The instructions would direct the consumer or medical personnel to administer the dosage form according to administration modes known to those skilled in the art. Such kits could advantageously be packaged and sold in single or multiple kit units. An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening. [0114] It may be desirable to provide a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested. Another example of such a memory aid is a calendar printed on the card, e.g., as follows “First Week, Monday, Tuesday, ... etc.... Second Week, Monday, Tuesday, ...” etc. Other variations of memory aids will be readily apparent. A “daily dose” can be a single tablet or capsule or several pills or capsules to be taken on a given day. Also, a daily dose of a first compound can consist of one tablet or capsule while a daily dose of the second compound can consist of several tablets or capsules and vice versa. The memory aid should reflect this. IV. Methods [0115] In a further aspect, a method for treating a hepatitis B infection in a patient in need thereof is provided, comprising administering to a subject or patient an effective amount of a disclosed compound, and/or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a hepatitis B infection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. [0116] With regard to HBV/HDV coinfection, HDV encodes HDAg, the HDV protein responsible for HDV RNA replication. HDV infection is facilitated by the interaction of HDAg with HBV viral envelope protein HBsAg, for both entry into the hepatocytes and assembly and release of the HDV virions. See for example, Negro, Cold Spring Harb Perspect Med.2014 Nov 3;4(11):a021550. doi: 10.1101/cshperspect.a021550, herein incorporated by reference with regard to such background teaching. Thus, because HDV infection is dependent on the presence of an existing HBV infection, strategies for treating HBV/HDV coinfection may focus on targeting HBV alone, HDV alone or both viruses together. [0117] Thus, the present disclosure also contemplates a method of treating an HBV or HDV infection, or HBV/HDV coinfection, in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and/or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for treating a HBV or HDV infection or HBV/HDV coinfection in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. [0118] Without being bound by any theory, methods of treatment may be facilitated by various mechanisms of action. One possibility for treatment involves targeting machinery involved in viral particle assembly. In the case of HBV, inhibiting assembly of the HBV envelope or core by targeting HBsAg would disrupt assembly of the HBV particles. A second strategy would be to inhibit viral replication of HBV and/or HDV. Existing antiviral therapies may apply this approach in the form of replication inhibitors that target, for example, a specific viral RNA polymerase. [0119] Thus, another aspect of the disclosure is a method for inhibiting HBV or HDV viral replication in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and/or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method for inhibiting HBV or HDV viral replication in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. [0120] Methods of treatment may further include targeting the network of bile acid transport proteins that are believed to be the “gateway” of entry for HBV or HDV infection into the hepatocyte. See for example, Slijepcevic et al., Digestive Diseases, 2017;35:251-258, herein incorporated by reference with regard to such background teaching. The bile acid transport system comprising the sodium taurocholate co-transporting polypeptide (NTCP) and apical sodium dependent bile acid transporter (ASBT) are a set of receptors that ensure effective bile acid transport between the ileum and hepatocyte. HBV/HDV coinfection of hepatocytes is believed to be mediated via the NTCP receptor, making it a possible target for treatment. Without being bound by any theory, an “entry inhibitor” may target any of the possible bile acid transport receptors, including, but not limited to the sodium taurocholate co-transporting polypeptide (NTCP) and apical sodium dependent bile acid transporter (ASBT) to prevent entry of either HBV or HDV virus into the cells. Such entry inhibitors may target all or a portion of the transport receptors to inhibit viral entry. [0121] Thus, another aspect of the disclosure is a method of inhibiting viral entry in hepatocytes in a patient in need thereof, comprising administering to a subject or patient an effective amount of a disclosed compound, and/or administering a first disclosed compound and optionally, an additional, different disclosed compound(s). In another embodiment, a method inhibiting viral entry in hepatocytes in a patient in need thereof is provided, comprising administering to a subject or patient a therapeutically effective amount of a disclosed pharmaceutical composition or a pharmaceutical composition comprising a disclosed compound, or two or more disclosed compounds, and a pharmaceutically acceptable excipient. [0122] Regardless of the mechanism targeted, treatment for patients dealing with HBV or HDV infection or HBV/HDV coinfection may be measured by seroconversion of any of the viral antigens, including but not limited to HBsAg or HBeAg, or maintenance of undetectable levels of these antigens. [0123] For use in accordance with the aspects described herein, the appropriate dosage of the compounds described herein is expected to vary depending on, for example, the particular compound employed, the mode of administration, and the nature and severity of the infection to be treated as well as the specific infection to be treated and is within the purview of the treating physician. Usually, an indicated administration dose may be in the range between about 0.1 to about 1000 μg/kg body weight. In some cases, the administration dose of the compound may be less than 400 μg/kg body weight. In other cases, the administration dose may be less than 200 μg/kg body weight. In yet other cases, the administration dose may be in the range between about 0.1 to about 100 μg/kg body weight. The dose may be conveniently administered once daily, or in divided doses up to, for example, four times a day or in sustained release form. [0124] A compound of the present disclosure may be administered by any conventional route, in particular: enterally, topically, orally, nasally, e.g., in the form of tablets or capsules, via suppositories, or parenterally, e.g., in the form of injectable solutions or suspensions, for intravenous, intra-muscular, sub-cutaneous, or intra-peritoneal injection. Suitable formulations and pharmaceutical compositions will include those formulated in a conventional manner using one or more physiologically acceptable carriers or excipients, and any of those known and commercially available and currently employed in the clinical setting. Thus, the compounds may be formulated for oral, buccal, topical, parenteral, rectal or transdermal administration or in a form suitable for administration by inhalation or insufflation (either orally or nasally). [0125] For oral administration, pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). Tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). Preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. [0126] Preparations for oral administration may also be suitably formulated to give controlled-release or sustained release of the active compound(s) over an extended period. For buccal administration the compositions may take the form of tablets or lozenges formulated in a conventional manner known to the skilled artisan. [0127] A disclosed compound may also be formulated for parenteral administration by injection e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain additives such as suspending, stabilizing and/or dispersing agents. Alternatively, the compound may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Compounds may also be formulated for rectal administration as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. [0128] Also contemplated herein are methods and compositions that include a second active agent or administering a second active agent. For example, in addition to being infected with HBV, a subject or patient can further have HBV infection-related co- morbidities, i.e., diseases and other adverse health conditions associated with, exacerbated by, or precipitated by being infected with HBV. Contemplated herein are disclosed compounds in combination with at least one other agent that has previously been shown to treat these HBV-infection-related conditions. [0129] In some cases, a disclosed compound may be administered as part of a combination therapy in conjunction with one or more antivirals. Example antivirals include nucleoside analogs, interferon α, and other assembly effectors, for instance heteroaryldihydropyrimidines (HAPs) such as methyl 4-(2-chloro-4-fluorophenyl)-6-methyl- 2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (HAP-1). For example, provided herein is a method of treating a patient suffering from hepatitis B infection comprising administering to the patient a first amount of a disclosed compound and a second amount of an antiviral, or other anti HBV agent, for example a second amount of a second compound selected from the group consisting of: an HBV capsid assembly promoter (for example, GLS4, BAY 41-4109, AT-130, DVR-23 (e.g., as depicted below),

NVR 3-778, NVR1221 (by code); and N890 (as depicted below):

other capsid inhibitors such as those disclosed in the following patent applications hereby incorporated by reference: WO2014037480, WO2014184328, WO2013006394, WO2014089296, WO2014106019, WO2013102655, WO2014184350, WO2014184365, WO2014161888, WO2014131847, WO2014033176, WO2014033167, and WO2014033170; Nucleos(t)ide analogs interfering with viral polymerase, such as entecavir (Baraclude), Lamivudine, (Epivir-HBV), Telbivudine (Tyzeka, Sebivo), Adefovir dipivoxil (Hepsera), Tenofovir (Viread), Tenofovir alafenamide fumarate (TAF), prodrugs of tenofavir (e.g. AGX-1009), L-FMAU (Clevudine), LB80380 (Besifovir) and:

viral entry inhibitors such as Myrcludex B and related lipopeptide derivatives; HBsAg secretion inhibitors such as REP 9AC’ and related nucleic acid-based amphipathic polymers, HBF-0529 (PBHBV-001), PBHBV-2-15 as depicted below:

and BM601 as depicted below:

disruptors of nucleocapsid formation or integrity such as NZ-4/W28F:

cccDNA formation inhibitors such as BSBI-25, CCC-0346, CCC-0975 (as depicted below):

[0130] HBc directed transbodies such as those described in Wang Y, et al, Transbody against hepatitis B virus core protein inhibits hepatitis B virus replication in vitro, Int. Immunopharmacol (2014), located at //dx.doi.org/10.1016/j.intimp.2015.01.028; antiviral core protein mutant (such as Cp183-V124W and related mutations as described in WO/2013/010069, WO2014/074906, each incorporated by reference); inhibitors of HBx- interactions such as RNAi, antisense and nucleic acid based polymers targeting HBV RNA;, e.g., RNAi (for example ALN-HBV, ARC-520, TKM-HBV, ddRNAi), antisense (ISIS- HBV), or nucleic acid based polymer: (REP 2139-Ca); immunostimulants such as Interferon alpha 2a (Roferon), Intron A (interferon alpha 2b), Pegasys (peginterferon alpha 2a), Pegylated IFN 2b, IFN lambda 1a and PEG IFN lambda 1a, Wellferon, Roferon, Infergen, lymphotoxin beta agonists such as CBE11 and BS1); Non-Interferon Immune enhancers such as Thymosin alpha-1 (Zadaxin) and Interleukin-7 (CYT107); TLR-7/9 agonists such as GS- 9620, CYT003, Resiquimod; Cyclophilin inhibitors such as NVP018; OCB-030; SCY-635; Alisporivir; NIM811 and related cyclosporine analogs; vaccines such as GS-4774, TG1050, Core antigen vaccine; SMAC mimetics such as birinapant and other IAP-antagonists; Epigenetic modulators such as KMT inhibitors (EZH1/2, G9a, SETD7, Suv39 inhibitors), PRMT inhibitors, HDAC inhibitors, SIRT agonists, HAT inhibitors, WD antagonists (e.g. OICR-9429), PARP inhibitors, APE inhibitors, DNMT inhibitors, LSD1 inhibitors, JMJD HDM inhibitors, and Bromodomain antagonists; kinase inhibitors such as TKB1 antagonists, PLK1 inhibitors, SRPK inhibitors, CDK2 inhibitors, ATM & ATR kinase inhibitors; STING Agonists; Ribavirin; N-acetyl cysteine ; NOV-205 (BAM205); Nitazoxanide (Alinia), Tizoxanide; SB 9200 Small Molecule Nucleic Acid Hybrid (SMNH); DV-601; Arbidol; FXR agonists (such as GW 4064 and Fexaramin); antibodies, therapeutic proteins, gene therapy, and biologics directed against viral components or interacting host proteins. [0131] In some embodiments, the disclosure provides a method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, and one or more other HBV agents each selected from the group consisting of HBV capsid assembly promoters, HBF viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg secretion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7/9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists. In some embodiments, the disclosure provides a method of treating a hepatitis B infection in a patient in need thereof, comprising administering an amount of a disclosed compound, and administering another HBV therapeutic. [0132] In some embodiments, the disclosure further provides a method of treating HBV or HDV infection or HBV/HDV coinfection in a patient in need thereof, comprising administering a first compound selected from any one of the disclosed compounds, and one or more other additional antivirals, the one or more additional antivirals include HDV therapies and one or more of HBV agents each selected from the group consisting of HBV capsid assembly promoters, HBF viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg secretion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7/9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists. In some embodiments, the disclosure provides a method of treating a HBV or HBV infection or HBV/HDV coinfection in a patient in need thereof, comprising administering an amount of a disclosed compound, and administering another HBV therapeutic or an HDV therapeutic. [0133] In some embodiments, the first and second amounts together comprise a pharmaceutically effective amount. The first amount, the second amount, or both may be the same, more, or less than effective amounts of each compound administered as monotherapies. Therapeutically effective amounts of a disclosed compound and antiviral may be co- administered to the subject, i.e., administered to the subject simultaneously or separately, in any given order and by the same or different routes of administration. In some instances, it may be advantageous to initiate administration of a disclosed compound first, for example one or more days or weeks prior to initiation of administration of the antiviral. Moreover, additional drugs may be given in conjunction with the above combination therapy. [0134] In another embodiment, a disclosed compound may be conjugated (e.g., covalently bound directly or through molecular linker to a free carbon, nitrogen (e.g., an amino group), or oxygen (e.g., an active ester) of a disclosed compound), with a detection moiety, for e.g., a fluorophore moiety (such a moiety may for example re-emit a certain light frequency upon binding to a virus and/or upon photon excitation). Contemplated fluorophores include AlexaFluor^® 488 (Invitrogen) and BODIPY FL (Invitrogen), as well as fluorescein, rhodamine, cyanine, indocarbocyanine, anthraquinones, fluorescent proteins, aminocoumarin, methoxycoumarin, hydroxycoumarin, Cy2, Cy3, and the like. Such disclosed compounds conjugated to a detection moiety may be used in e.g., a method for detecting HBV or biological pathways of HBV infection, e.g., in vitro or in vivo; and/or methods of assessing new compounds for biological activity. V. Examples [0135] The compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials. [0136] At least some of the compounds identified as “intermediates” herein are contemplated as compounds of the disclosure. Abbreviations: AcOH Acetic acid ACN Acetonitrile Boc₂O Di-tert-butyl dicarbonate nBuLi n-Butyllithium DCM Dichloromethane DIAD Diisopropyl azodicarboxylate DIEA Diisopropyl ethylamine DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide DPPF 1,1’-Bis(diphenylphosphino)ferrocene EA, EtOAc Ethyl acetate Et₃N Triethylamine HATU Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium h, hr Hour(s) HPLC High performance liquid chromatography LCMS Liquid chromatography–mass spectrometry MeOH Methanol NMO N-Methylmorpholine-N-Oxide NBS N-Bromosuccinimide PE Petroleum ether iPrOH Isopropanol rt, r.t. Room temperature SFC Supercritical Fluid Chromatography TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran TLC Thin-layer chromatography XPhos 2-Dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl [0137] Example 1.3-(3-Butyl-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)benzoic acid

[0138] Step 1. Synthesis of 2-((tert-butoxycarbonyl)amino)hexanoic acid (1-2). То а solution of 2-aminohexanoic acid (25 g, 0.19 mol) in water (250 mL) and THF (250 mL), NaHCO₃ (48 g, 0.57 mol) and Boc-anhydride (52.2 ml, 0.23 mol) were added, and the reaction mixture was stirred at rt for 16 hr. After completion, the reaction mixture was cooled, quenched, and acidified with sat aq. NaHSO₄. The reaction mixture was extracted with EtOAc (100 mL x 3). The combined organic layer was washed with ice-cold water (150 mL) and brine (150 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuo to give crude 1-2 (42 g, 95%) as a pale-yellow oil, which was used for the next step without further purification. [0139] Step 2. Synthesis of tert-butyl (1-oxo-1-(phenylamino)hexan-2-yl)carbamate (1- 3). A solution of 2-((tert-butoxycarbonyl)amino)hexanoic acid (1-2) (5 g, 0.02 mol) in CH₂Cl₂ (150 mL) was cooled to 0 °C and then added EDC·HCl (5.0 g, 26 mmol), HOBt (7.2 g, 22 mmol), and TEA (5 g, 50 mmol). After stirring at 0 °C for 1 hr, aniline (1.86 g, 20 mmol) was added, and the resulting mixture was stirred at rt overnight. Subsequently, the reaction mixture was washed with sat. aq. NaHCO₃ (100 mL x 2) and water (100 mL) and dried over anhydrous Na₂SO₄. The solvent was removed, and the residue was dried in vacuo to give crude 1-3 (6.0 g, 90%) as a pale-yellow oil, which was used for the next step without further purification. [0140] Step 3. Synthesis of 2-amino-N-phenylhexanamide (1-4). To а solution of tert- butyl (1-oxo-1-(phenylamino)hexan-2-yl)carbamate (1-3) (6.0 g, 19.6 mol) in 1,4-dioxane (500 mL) at 0°C, а solution of HCl in 1,4-dioxane (4 N, 199 mL). After stirring at rt for 16 hr, the reaction mixture was concentrated. The residue was treated with sat. aq. NaHCO₃ to adjust pH 8, and the resulting mixture was extracted with EtOAc (100 mL x 3). The combined organic layer was washed brine (100 mL) and dried over anhydrous Na₂SO₄. The solvent was removed, and the residue was dried in vacuo to give crude 1-4 (3.8 g, 95%) as a brown oil, which was used for the next step without further purification. [0141] Step 4. Synthesis of N¹-phenylhexane-1,2-diamine (1-5). То а solution of 2- amino-N-phenylhexanamide (1-4) (10 g, 0.05 mol) in THF (320 mL) at 0 °C was added borane dimethylsulfide (2М solution in THF, 117 ml, 0.23 mol) and the reaction mixture was stirred at 75 °C for 16 hr. Subsequently, the reaction mixture was cooled to rt and then quenched with methanol (150 mL). The mixture was stirred at rt for 30 min and then concentrated. and then stirred for 30 min at rt. The reaction mixture concentrated under vacuum. The residue was mixed with aq. HCl (3 М, 100 mL), and the resulting mixture was extracted with adjust to pH 9 with sat. aq. NaOH. Subsequently, the mixture was extracted with EtOAc (100 mL x 3). The combined organic layer was washed brine (200 mL) and dried over anhydrous Na₂SO₄. The solvent was removed, and the residue was dried vacuo to give crude 1-5 (8 g, 85%) as a brown oil, which was used for the next step without further purification. [0142] Step 5. Synthesis of 2,4-dibromo-5-methoxy-N-(1-(phenylamino)hexan-2- yl)benzenesulfonamide (1-6). То а solution of 2,4-dibromo-5-methoxybenzenesulfonyl chloride (52 g, 0.14 mol) in THF (500 mL) at 0 °C were added N¹-phenylhexane-1,2-diamine (21 g, 0.11 mol) and triethylamine (45.5 ml, 0.33 mol). After stirring at rt for 4 hr, the reaction mixture was concentrated. The residue was dissolved in EtOAc (400 mL) and the solution was washed with water (200 mL) and brine (200 mL), dried over anhydrous Na₂SO₄ and concentrated. The residue was dried in vacuo to give crude 1-6 (65 g, 65 %) as a brown solid, which was used for the next step without further purification. MS (ESI): calcd. for C₁₉H₂₄Br₂N₂O₃S: 518; Found: 520 [M + 2]⁺. [0143] Step 6. Synthesis of 7-bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepine 1,1-dioxide (1-7). То а solution of 2,4-dibromo-5- methoxy-N-(1-(phenylamino)hexan-2-yl)benzenesulfonamide (1-6) (65 g, 0.11 mol) in DMF (200 mL), K₂CO₃ (58 g, 0.42 mol) and copper powder (14.1 g, 0.22 mol) were added. The reaction mixture was degassed for 5 min under N₂ atmosphere, and the reaction mixture was then stirred at 115 °C for 16 hr. Next, the reaction mixture was cooled to rt and quenched with ice-cold water (500 mL). The aqueous layer was extracted with MTBE (150 mL x 3). The combined organic layer was washed with brine (300 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel column chromatography using EtOAc/Hexanes as eluent to give 1-7 (20 g, 43%) as an off-white solid. MS (ESI): calcd. for C₁₉H₂₃BrN₂O₃S: 438; Found: 440 [M + 2]⁺; ¹H NMR (400 MHz, DMSO-d₆): δ 7.60 (d, J = 2.1 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.43 (d, J = 9.0 Hz, 1H), 7.20 – 7.11 (m, 2H), 6.73 (t, J = 7.3 Hz, 1H), 6.60 (d, J = 8.1 Hz, 2H), 4.34 (d, J = 15.5 Hz, 1H), 3.95 (d, J = 2.1 Hz, 3H), 2.86 (s, 1H), 1.57 (s, 1H), 1.49 – 1.24 (m, 5H), 0.89 (td, J = 7.2, 2.0 Hz, 3H) ppm [0144] Step 7: Synthesis of 7-bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (1-8). То а stirred solution of 7-bromo- 3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothia-diazepine 1,1-dioxide (1-7) (10 g, 22.75 mmol) in DMF (50 mL) was added Сs₂СОз (14.75 g, 45.67 mmol), followed by iodomethane (7.1 mL, 0.11 mol). After stirring at 60 °C for 16 hr, the reaction mixture was concentrated. The residue was diluted with water (50 mL) and extracted with MTBE (100 mL x 3). The combined organic layer was washed with brine (250 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuo to give 1-8 (7.0 g, 68%) as a yellow solid. MS (ESI): calcd. for C₂₀H₂₅BrN₂O₃S: 452; Found: 454 [M + 2]⁺; ¹H NMR (400 MHz, CD₃OD): δ 7.51 (d, J = 2.2 Hz, 2H), 7.20 (t, J = 7.9 Hz, 2H), 6.80 (t, J = 7.3 Hz, 1H), 6.69 (d, J = 8.2 Hz, 2H), 4.08 (d, J = 16.0 Hz, 1H), 3.99 (s, 4H), 3.26 (s, 1H), 2.59 (s, 3H), 1.61 (d, J = 8.2 Hz, 2H), 1.53 – 1.34 (m, 4H), 0.97 (t, J = 6.5 Hz, 3H) ppm. [0145] Step 8. Synthesis of 7-bromo-3-butyl-8-hydroxy-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (1-9). To a DCM (10 mL) solution of 7-bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (1-8) (700 mg, 1.54 mmol) was added tribromoborane (1.55 g, 6.17 mmol) dropwise under an atmosphere of Ar. Upon completion, the mixture was allowed to warm up to rt and stirred for 18 hr. Subsequently, the reaction mixture was diluted with saturated aq. NaHCO₃ and DCM (25 mL). The separated organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuo to give crude 1-9 (1.0 g, 84%) as a brown solid, which was used in the next step without further purification. MS (ESI): calcd. for C₁₉H₂₃BrN₂O₃S: 438; Found: 440 [M + 2]⁺. [0146] Step 9. Synthesis of 3-butyl-8-hydroxy-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepine 1,1-dioxide (1-10).7-Bromo-3-butyl-8-hydroxy-2- methyl-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (1-9) (1.0 g, 2.28 mmol) was dissolved in methanol (30 mL) and treated with 5% Pd/C. The resulting mixture was stirred at rt under an atmosphere of H₂ overnight. The reaction mixture was saturated with N₂ and filtered through a celite 545^® plug, and the filtered cake was washed with EtOAc (10 mL x 3). The filtrate was concentrated, and the residue was purified by preparative HPLC to give 1-10 (400 mg, 70%) as an off-white solid. MS (ESI): calcd. for C₁₉H₂₄N₂O₃S: 360; Found: 361 [M + 1]⁺. [0147] Step 10. Synthesis of 3-butyl-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl trifluoromethanesulfonate (1-11). A solution of 3-butyl-8-hydroxy-2-methyl-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]-thiadiazepine 1,1- dioxide (1-10) (100 mg, 277 µmol) and pyridine (33 mg, 417 µmol) in DCM (10 mL) was added trifluoromethanesulfonic anhydride (94.17 mg, 334 µmol) at 0 °C. After stirring at rt for 2 hr, the reaction mixture was added sat. aq. NaHCO₃ (10 mL) and DCM (15 mL). The resulting mixture was stirred for 30 min. The separated organic layer was washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed, and the residue was dried in vacuo to give crude 1-11 (140 mg, 93%) as a brown oil, which was used for the next step without further purification. MS (ESI): calcd. for C₂₀H₂₃F₃N₂O₅S₂: 492; Found: 493 [M + 1]⁺. [0148] Step 11. Synthesis of 3-(3-butyl-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)benzoic acid (Example 1). A suspension of 3- butyl-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl trifluoromethanesulfonate (1-11) (140 mg, 284 µmol), methyl 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzoate (298 mg, 1.14 mmol), cesium carbonate (370 mg, 1.14 mmol), and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) dichloromethane adduct (23.2 mg, 28.41 µmol) in degassed dioxane/water = 5/1 (v/v) was stirred at 90 °C under Ar overnight. The mixture was cooled to rt and concentrated. The residue was diluted with EtOAc (25 mL), and the resulting solution was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by preparative HPLC to give Example 1 (60 mg, 45%) as an off-white solid. MS (ESI): calcd. for C₂₆H₂₈N₂O₄S: 464; Found: 463 [M - 1]⁻; ¹H NMR (400 MHz, DMSO-d₆): δ 13.20 (s, 1H), 8.22 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 8.06 – 7.91 (m, 3H), 7.65 (t, J = 7.7 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.22 (t, J = 7.7 Hz, 2H), 6.81 (d, J = 8.0 Hz, 3H), 4.14 (d, J = 16.0 Hz, 1H), 3.81 (s, 1H), 3.43 (s, 1H), 2.59 (d, J = 5.1 Hz, 3H), 1.60 (d, J = 9.6 Hz, 2H), 1.34 (dq, J = 14.1, 7.1 Hz, 4H), 0.92 (d, J = 7.0 Hz, 3H) ppm. [0149] Example 2.3-(3-Butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)benzoic acid

[0150] Step 1. Synthesis of 2,4,5-tribromoaniline (2-2). To a stirred suspension of 2,5- dibrooaniline (2-1) (81 g, 323 mmol) in CCl₄ (1200 mL) was added a solution of Br₂ (54.2 g, 338.8 mmol) in CCl₄ (400 mL) at 0ºC. The reaction mixture was allowed to stir at rt for 1.5 hr. Subsequently, aq. NaOH (1M, 800 mmol) was added to the reaction mixture under vigorous stirring, followed by CHCl₃ (500 mL). After the solution became clear, the phases were allowed to separate. The water phase was extracted by chloroform (300 mL) and the combined organic layers was washed sequentially by water and brine, dried over anhydrous Na₂SO₄, concentrated. The residue was purified by silica gel column chromatography using EtOAc/Hexanes as eluent to give 2-2 (54 g, 51%) as a yellow solid. [0151] Step 2. Synthesis of 2,4,5-tribromobenzene-1-sulfonyl chloride (2-3). A suspension of 2,4,5-tribromoaniline (2-2) (54 g, 163.6 mmol) in a mixture of aq. HCl (5N, 540 mL) and glacial acetic acid (60 mL) was heated overnight at 70 ºC under stirring until the appropriate hydrochloride salt was formed. Then an aqueous solution of SO₂/HCl was prepared by careful quenching of SO₂Cl₂ (194.7 g, 1.636 mol) in ice water (800 g), followed by stirring the mixture for 2 hr. To a stirred suspension of the HCl salt of 2,4,5- tribromoaniline (2-2) was added aq. NaNO₂ (13.55g, 196.4 mmol in 100 mL of water) at 0 - 5 ºC, and the reaction mixture was stirred at this temperature for 1 hr. Subsequently, the cooled diazonium salt solution was added gradually upon stirring to the previously prepared and ice cooled aqueous solution of SO₂/HCl and CuCl (1.62g, 16.36 mmol). After completion, the viscous mixture was extracted by CH₂Cl₂ (300 mL x 3), and the combined organic extracts was sequentially washed with sat. aq. NaHCO₃ (150 mL x 2), water and brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel column chromatography using EtOAc/Hexanes as eluent to give 2-3 (29.3 g, 43%) as a yellow solid. [0152] Step 3. Synthesis of 2,4,5-tribromo-N-(1-(phenylamino)hexan-2- yl)benzenesulfonamide (2-4). To a mixture of 2,4,5-tribromobenzene-1-sulfonyl chloride (2- 3) (29.3 g, 70.9 mmol) and triethylamine (14.3 g, 141.8 mmol) in THF (300 mL), N¹- phenylhexane-1,2-diamine (1-5) (13.6 g, 70.9 mmol) was added dropwise at 0 °C. After stirring at rt overnight, the reaction mixture was concentrated, and the residue was diluted with CH₂Cl₂ (500 mL). The mixture was washed with sat. aq. NaHCO₃, water and brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel column chromatography using EtOAc/Hexanes as eluent to give 2-4 (37 g, 92%) as a yellow solid. MS (ESI); calcd. for C₁₈H₂₁Br₃N₂O₂S: 566; Found: 568 [M + 2]⁺. [0153] Step 4. Synthesis of 7,8-dibromo-3-butyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-5). То а solution of 2,4,5-tribromo- N-(1-(phenylamino)hexan-2-yl)benzenesulfonamide (2-4) (37 g, 65 mmol) in DMF (370 mL), K₂CO₃ (17.94 g, 130 mmol) and copper powder (4.13 g, 65 mmol) were added. The reaction mixture was degassed with N₂ for 5 min and the resultin mixture was stirred at 115°C for 16 he under an atmosphere of N₂. Subsequently, the reaction mixture was quenched with ice-cold water (1000 mL) and then extracted with MTBE (300 mL x 3). The combined organic layer was washed with brine (300 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuo to give crude 2-5 (31g, 98%) as a brown solid, which was used for the next step without further purification. MS (ESI): calcd. for C₁₈H₂₀Br₂N₂O₂S: 486; Found: 488 [M + 2]⁺. [0154] Step 5. Synthesis of 7,8-dibromo-3-butyl-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepine 1,1-dioxide (2-6). То а stirred solution of 7,8- dibromo-3-butyl-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-5) (31 g, 63.5 mmol) in DMF (310 mL) were added Сs₂СОз (51.75 g, 158.75 mmol) and iodomethane (45.09 g, 317.5 mmol). The reaction mixture was allowed to stir at 50 °C for 16 hr. Subsequently, the reaction mixture was concentrated, and the residue was diluted with water (250 mL) and MTBE (250 mL). The aqueous layer was extracted with MTBE (250 mL x 3) and the combined organic extracts were washed with brine (250 mL x 2), dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuo to give 2-6 (30 g, 97%) as a yellow solid. MS (ESI): calcd. for C₁₉H₂₂Br₂N₂O₂S: 500; Found: 503 [M + 3]⁺; ¹H NMR (500 MHz, DMSO-d₆): δ 8.02 (s, 1H), 7.54 (s, 1H), 7.24 (t, J = 7.8 Hz, 2H), 6.87 (dd, J = 21.7, 7.7 Hz, 2H), 4.06 (d, J = 16.1 Hz, 1H), 3.68 (s, 1H), 3.45 (s, 1H), 2.58 (s, 3H), 1.53 (d, J = 9.2 Hz, 2H), 1.30 (d, J = 10.7 Hz, 4H), 0.90 – 0.76 (m, 3H) ppm. [0155] Step 6. Synthesis of 8-bromo-3-butyl-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5- tetrahydrobenzo-[f][1,2,5]thiadiazepine 1,1-dioxide (2-7). A gaseous methylmercaptane (generated from sodium mercaptane 21% aqueous solution by means of dropwise addition into anhydrous orthophosphoric acid) was bubbled through suspension of sodium hydride (60% in mineral oil) (0.26 g, 5.98 mmol) in anhydrous DMF (45 mL) at rt until the total dissolution of solid occurred. Next, 7,8-dibromo-3-butyl-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepine 1,1-dioxide (2-6) (3 g, 5.98 mmol) was added in one portion. After stirring at rt overnight, the reaction mixture was quenched by water (150 mL) and extracted by MTBE (150 mL x 3). The combined organic layer was washed sequentially with water (100 mL x 3) and brine (100 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuum to give 2-7 (2.6 g, 93% ) as a yellow solid. MS (ESI): calcd. for C₂₀H₂₅BrN₂O₂S₂: 468; Found: 470 [M + 2]⁺. [0156] Step 7. Synthesis of 3-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)benzoic acid (Example 2). A mixture of 8- bromo-3-butyl-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-7) (0.19 g, 0.405 mmol), 3-carboxy- phenyl-boronic acid (0.100 g, 0.608 mmol), potassium phosphate (0.26 g, 1.22 mmol), and Pd(dppf)Cl₂ (0.017 g, 0.0203 mmol) in dioxane (2.55 mL) and water (0.85 mL) was degassed with N₂ and the resulting mixture was stirred at 100 °C for 16 hr under an atmosphere of N₂. Next, the reaction mixture was quenched by adding the excess HCl/dioxane (10 % solution) (1.8 mL) and evaporated to dryness. The residue was purified by preparative HPLC to give Example 2 (87 mg, 42%). MS (ESI): calcd. for C₂₇H₃₀N₂O₄S₂: 510; Found: 509 [M -1]-; ¹H NMR (400 MHz, DMSO-d₆): δ 13.14 (s, 1H), 8.01 (d, J = 8.3 Hz, 2H), 7.72 (d, J = 7.6 Hz, 1H), 7.63 (t, J = 7.6 Hz, 1H), 7.58 (s, 1H), 7.23 (t, J = 7.8 Hz, 2H), 7.18 (s, 1H), 6.81 (t, J = 6.6 Hz, 3H), 4.11 (d, J = 16.0 Hz, 1H), 3.83 (s, 1H), 2.46 (s, 3H), 2.33 (s, 3H), 1.68 – 1.50 (m, 2H), 1.34 (d, J = 17.9 Hz, 4H), 0.91 (t, J = 6.7 Hz, 3H) ppm. [0157] Example 3.3-(3-Butyl-7-fluoro-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)benzoic acid

[0158] Step 1. Synthesis of 3-butyl-7-fluoro-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl trifluoromethanesulfonate (3-2). To a solution of 3-butyl-7-fluoro-8-hydroxy-2-methyl-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (3-1) (100 mg, 264 µmol), which was prepared by following the procedure for preparing 7-bromo-3-butyl-8-hydroxy-2-methyl-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (1-9) as described in Scheme 1 and replacing 2,4-dibromo-5-methoxybenzenesulfonyl chloride with 2-bromo-4- fluoro-5-methoxybenzenesulfonyl chloride, and pyridine (32 mg, 397 µmol) in DCM (10 mL) was added trifluoromethanesulfonic anhydride (90 mg, 317 µmol) at 0 °C. After stirring at rt for 2 hr, the reaction mixture was diluted with DCM (15 mL), washed with sat. aq. NaHCO₃ (15 mL x 2) and water (15 mL x 2), dried over anhydrous Na₂SO₄, and concentrated. The residue was dried in vacuo to give crude 3-2 (140 mg) as a brown oil, which was used for the next step without further purification. [0159] Step 2. Synthesis of methyl 3-(3-butyl-7-fluoro-2-methyl-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)benzoate (3-3). A mixture of 3-butyl-7- fluoro-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl trifluoromethanesulfonate (3-2) (140 mg, 274 µmol), methyl 3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzoate (287 mg, 1.09 mmol), cesium carbonate (356.5 mg, 1.09 mmol), and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) dichloromethane adduct (23 mg, 24 µmol) in dioxane/water = 5/1 (v/v) (10 mL) was degassed with Ar and then stirred at 90 °C overnight under an atmosphere of Ar. The mixture was concentrated, and the residue was diluted wither EtOAc (25 mL), washed with water and brine, dried over sodium sulfate, and concentrated. The residue was dried in vacuo to give crude 3-3 (200 mg, 76%) as a yellow solid, which was used in the next step without further purification. [0160] Step 3. Synthesis of 3-(3-butyl-7-fluoro-2-methyl-1,1-dioxo-5-phenyl-2,3,4,5- tetrahydro-1lambda6,2,5-benzothiadiazepin-8-yl)benzoic acid (Example 3). A mixture of methyl 3-(3-butyl-7-fluoro-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)benzoate (3-3) (200 mg, 403 µmol) and lithium hydroxide (48 mg, 2 mmol) in dioxane/water = 2/1 (v/v) (5 mL) was stirred at rt overnight. The reaction mixture was treated with 0.1 N aq. HCl and adjusted to pH 4. The mixture was concentrated, and the residue was purified by preparative HPLC to give Example 3 (50 mg, 26%) as an off-white solid. MS (ESI): calcd. for C₂₆H₂₇FN₂O₄S: 482; MS Found: 481 [M - 1]⁻; ¹H NMR (400 MHz, DMSO-d₆): δ 13.20 (s, 1H), 8.12 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.66 (t, J = 7.7 Hz, 1H), 7.28 (t, J = 7.8 Hz, 2H), 7.21 (d, J = 11.8 Hz, 1H), 6.93 (dd, J = 14.0, 7.5 Hz, 3H), 4.13 (d, J = 16.3 Hz, 1H), 3.75 (s, 1H), 3.55 (s, 1H), 2.63 (s, 3H), 1.58 (d, J = 7.6 Hz, 2H), 1.33 (d, J = 9.5 Hz, 4H), 0.90 (t, J = 6.9 Hz, 3H) ppm. [0161] Example 4.3-(3-Butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)-1-methyl-1H-pyrazole-5-carboxylic acid

[0162] Step1. Synthesis of 3-butyl-2-methyl-7-(methylthio)-5-phenyl-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1- dioxide (4-1). To a solution of 8-bromo-3-butyl-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-7) (936 mg, 2.0 mmol) in anhydrous THF (20 mL) was added n-BuLi (2.5 N, 2.8 mmol) at -78 °C under an atmosphere of N₂. After stirring at -78 °C for 20 min, a solution of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2- dioxaborolane (2.6 g, 14 mmol) in anhydrous THF (15 mL) was added. The resulting mixture was stirred at rt for 2 hr and then quenched by adding saturated aq. NH₄Cl (5 mL). The mixture was concentrated, and the residue was diluted with EtOAc (100 mL), washed with brine (50 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel column chromatography using EtOAc/Petroleum Ether = 1/5 (v/v) as eluent to give 4-1 (700 mg, 67 %) as a white solid. MS (ESI): calcd. for C₂₆H₃₇BN₂O₄S₂: 516; Found: 517 [M+1] ⁺. [0163] Step 2. Synthesis of ethyl 3-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1-methyl-1H-pyrazole-5-carboxylate (4- 2). To a solution of 3-butyl-2-methyl-7-(methylthio)-5-phenyl-8-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (4-1) (150 mg, 0.29 mmol), ethyl 3-iodo-1-methyl-1H-pyrazole-5-carboxylate (162 mg, 0.58 mmol), K₂CO₃ (120 mg, 0.87 mmol) in dioxane (5 mL) and water (1 mL) was added Pd(dppf)Cl₂ (21 mg, 0.029 mmol), and the reaction mixture was degassed with N₂ and stirred at 100 °C for 16 hr. Subsequently, the reaction mixture was concentrated, and the residue was diluted with EtOAc (20 mL) and water (10 mL). The organic layer was washed brine (20 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel column chromatography using EtOAc/Petroleum Ether = 1/1 (v/v) as eluent to give 4-2 (130 mg, 83%) as an off-white solid. MS (ESI): calcd. for C₂₇H₃₄N₄O₄S₂: 542; Found: 543 [M + 1]⁺. [0164] Step 3. Synthesis of 3-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1-methyl-1H-pyrazole-5-carboxylic acid (Example 4). A mixture of ethyl 3-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1-methyl-1H-pyrazole-5- carboxylate (4-2) (120 mg, 0.22 mmol) and LiOH^.H₂O (28 mg, 0.66 mmol) in THF (2 mL), MeOH (0.5 mL) and water (2 mL) was stirred at rt for 16 hr. The resulting mixture was adjusted to pH = 5 by adding sat. aq. KHSO₄ and extracted with EtOAc (10 mL x 3). Subsequently, the combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by preparative HPLC to give Example 4 (40 mg, 32%) as a white solid. MS (ESI): calcd. for C₂₅H₃₀N₄O₄S₂: 514; Found: 515 [M + 1]⁺; ¹H NMR (MeOH-d₄, 400 MHz): δ 7.70 (s, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.08 ‒ 6.96 (m, 4H), 6.80 (s, 1H), 4.15 (d, J = 6.8 Hz,1H), 3.86 ‒ 3.66 (m, 5H), 2.74 (s, 3H), 2.24 (s, 3H), 1.76 ‒ 1.65 (m, 1H), 1.60 ‒ 1.30 (m, 5H), 0.95 (t, J = 7.2 Hz, 3H) ppm. [0165] Example 5.1-(3-Butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1H-pyrazole-4-carboxylic acid

[0166] Step 1. Synthesis of ethyl 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1H-pyrazole-4-carboxylate (5-1). To a solution of 8-bromo-3-butyl-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-7) (200 mg, 0.43 mmol) in dry DMF (6 mL) was added ethyl 1H-pyrazole-4-carboxylate (120 mg, 0.85 mmol), Cs₂CO₃ (278 mg, 0.85 mmol), and Cu (28 mg, 0.0.43 mmol), the reaction mixture was stirred at 115 °C overnight under an atmosphere of Ar. Subsequently, the reaction mixture was diluted with EtOAc (20 mL), washed with water (20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by preparative TLC to give 5-1 (35 mg, 16%) as a yellow solid. MS (ESI): calcd. for C₂₆H₃₂N₄O₄S₂: 528; Found: 529 [M + 1]⁺; ¹H NMR (400 MHz, CDCl₃): δ 8.25 (s, 0.42 H), 8.20 (s, 0.56 H), 8.14 (s, 0.55 H), 8.07 (s, 0.38 H), 7.92 (s, 0.42H), 7.91 (s, 0.57H), 7.35 ‒ 7.27 (m, 2H), 7.20 (s, 0.44H), 7.05 ‒ 6.89 (m, 3.64 H), 4.37 ‒ 4.28 (m, 2H), 4.06 (d, J = 14.4 Hz, 1H), 3.86 ‒ 3.54 (m, 2H), 2.76 (s, 1.63 H), 2.75 (s, 1.34 H), 2.47 (s, 1.24H), 2.19 (s, 1.70H), 1.76 ‒ 1.66 (m, 1H), 1.52 ‒ 1.44 (m, 2H), 1.40 ‒ 1.32 (m, 6H), 0.96 ‒ 0.86 (m, 3H) ppm. [0167] Step 2. Synthesis of 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1H-pyrazole-4-carboxylic acid (Example 5). A mixture of ethyl 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)-1H-pyrazole-4-carboxylate (5-1) (35 mg, 0.07 mmol) and LiOH^.H₂O (56 mg, 1.33 mmol) in MeOH (5 mL) and water (1 mL) was stirred at 45 °C overnight. Subsequently, the mixture was adjusted to pH= 5 with aq.2 N HCl and extracted with EA (15 mL x 2). The combined organic extracts were washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified preparative HPLC to give Example 5 (31 mg, 94%) as a light-yellow solid. MS (ESI): calcd. for C₂₄H₂₈N₄O₄S₂: 500; Found: 501 [M + 1]⁺; ¹H NMR (400 MHz, CDCl₃): δ 8.33 (s, 0.49H), 8.28 (s, 0.51H), 8.19 (s, 0.51H), 8.12 (s, 0.50H), 7.93 (s, 1H), 7.37 ‒ 7.28 (m, 2H), 7.22 (s, 0.50H), 7.07 ‒ 6.95 (m, 2H), 6.95 ‒ 6.89 (m, 1.51H), 4.06 (d, J = 13.6 Hz, 1H), 3.85 ‒ 3.58 (m, 2H), 2.78 (s, 1.48H), 2.76 (s, 1.57H), 2.48 (s, 1.48H), 2.20 (s, 1.53H), 1.77 ‒ 1.65 (m, 1H), 1.55 ‒ 1.45 (m, 2H), 1.42 ‒ 1.32 (m, 3H), 0.96 ‒ 0.89 (m, 3H) ppm. [0168] Example 6.1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)azetidine-3-carboxylic acid

[0169] Step 1. Synthesis of methyl 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)azetidine-3-carboxylate (6-1). A mixture of 8-bromo-3-butyl-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-7) (24.2 mg, 159.63 µmol), cesium carbonate (104.02 mg, 319.25 µmol), Pd2(dba)3 (4.87 mg, 5.32 µmol) and [5- (diphenylphosphanyl)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphane (6.16 mg, 10.64 µmol) in dioxane (5 mL) was degassed with Ar and then stirred at 100 °C for 16 hr. Subsequently, the mixture was diluted with EtOAc (25 mL), washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by preparative HPLC to give 6-1 (29 mg, 54%) as an off-white solid. MS (ESI): calcd. for C₂₅H₃₃N₃O₄S₂: 503; Found: 502 [M-1]-. [0170] Step 2: Synthesis of 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)azetidine-3-carboxylic acid (Example 6). A mixture of methyl 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)azetidine-3-carboxylate (6-1) (29 mg, 58 µmol) and lithium hydroxide (10 mg, 230 µmol) in 1,4-dioxane/water = 4/1 (v/v) (3 mL) was stirred at rt for 2 hr. Subsequently, the reaction mixture was acidified with aq.3N HCl to pH 4 and then concentrated. The residue was purified by preparative HPLC to give Example 6 (16 mg, 58%). MS (ESI): calcd. for C₂₄H₃₁N₃O₄S₂: 489; Found: 488 [M - 1]⁻; ¹H NMR (400 MHz, CD₃CN): δ 7.23 – 7.16 (m, 2H), 7.13 (s, 1H), 7.03 (s, 1H), 6.74 (t, J = 7.3 Hz, 1H), 6.60 (d, J = 8.2 Hz, 2H), 4.28 (dt, J = 15.8, 8.1 Hz, 2H), 4.19 (dd, J = 7.5, 5.9 Hz, 1H), 4.14 (dd, J = 7.5, 5.9 Hz, 1H), 4.08 – 4.01 (m, 1H), 3.98 (d, J = 16.1 Hz, 1H), 3.52 (tt, J = 8.5, 5.9 Hz, 1H), 3.20 (t, J = 13.2 Hz, 1H), 2.50 (s, 3H), 2.41 (s, 3H), 1.66 – 1.53 (m, 2H), 1.44 (tdd, J = 21.1, 11.2, 5.2 Hz, 4H), 0.98 (t, J = 6.8 Hz, 3H) ppm. [0171] Example 7.3-((3-Butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)amino)benzoic acid

[0172] Step 1. Synthesis of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)amino)benzoate (7-1). In 50 mL flask, methyl 3-aminobenzoate (22 mg, 0.15 mmol) and 2-7 (50 mg, 0.1 mmol) were suspended in dioxane (30 mL) and degassed by vacuum/argon purge cycle. In a flow of Ar, Pd(dppf)Cl₂ (0.05 eq.) and XantPhos (0.1eq.) were added, followed by Cs₂CO₃ (200 mg, 0.6 mmol). The reaction mixture was refluxed for 12 h, then cooled to rt, concentrated, and partitioned between MTBE (20 mL) and water (10 mL). The organic layer was separated, dried over Na₂SO₄, and concentrated in vacuo to give crude 7-1 (100 mg) as a brown solid. MS (ESI): calcd. for C₂₈H₃₃N₃O₄S₂: 539; Found: 538 [M-1]⁻. [0173] Step 2. Synthesis of 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)amino)benzoic acid (Example 7). То а stirred solution of 7-1 (100 mg) in 1, 4-dioxane/water (4:1 (v/v), 5 mL), lithium hydroxide (6 mg, 0.26 mmol) was added, and the reaction mixture was stirred at rt overnight. Subsequently, the reaction mixture was acidified with dilute 1.5N aq. HCI to pH ~4 and diluted with ice cold water (5 mL). The aqueous layer was extracted with EtOAc (5 mL x 2), and then the combined organic layer was washed with water (5 mL) and brine solution (5 mL). The organic part was dried over anhydrous Na₂SO₄ and concentrated. The resulting residue was purified by preparative HPLC to give Example 7 (16 mg) as a light brown solid. MS (ESI): calcd. for C₂₇H₃₁N₃O₄S₂: 525; Found: 524 [M-1]⁻; ¹H NMR (400 MHz, DMSO- d6): δ 12.86 (s, 1H), 7.94 (s, 1H), 7.58 (s, 1H), 7.52 (s, 1H), 7.41 (d, J = 7.3 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.26 – 7.06 (m, 4H), 6.72 (t, J = 7.2 Hz, 1H), 6.66 (d, J = 8.3 Hz, 2H), 4.04 (d, J = 16.6 Hz, 1H), 3.87 (s, 1H), 3.25 (s, 1H), 2.45 (s, 3H), 2.40 (s, 3H), 1.62 (s, 1H), 1.51 (s, 1H), 1.35 (s, 4H), 0.91 (s, 3H) ppm. [0174] Example 8.3-((3-Butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)oxy)benzoic acid

[0175] Step 1. Synthesis of 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)benzoic acid (Example 8). To a stirred solution of 8-1 (60.0 mg, 147.58 µmol), which was readily prepared from 3-butyl-7- fluoro-8-methoxy-2-methyl-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1- dioxidewith NaSMe at 80 °C in DMF, in 1,4-dioxane, 3-iodobenzoic acid (43.91 mg, 177.04 µmol), cesium carbonate (96.14 mg, 295.06 µmol), copper(I) iodide (2.81 mg, 14.75 µmol) and N1,N2-dimethylcyclohexane-1,2-diamine (2.1 mg, 14.75 µmol) were added under argon. The resulting mixture was stirred at 90°C overnight and concentrated. The residue was purified by preparative HPLC to give Example 8 (2.4 mg, 2.9%) as an off-white solid. MS (ESI): calcd. for C₂₇H₃₀N₂O₅S₂: 526; Found: 525 [M-1]-; 1H NMR (400 MHz, CD3CN): δ 7.84 (d, J = 7.6 Hz, 1H), 7.64 (s, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.35 – 7.28 (m, 1H), 7.28 – 7.21 (m, 3H), 6.82 (t, J = 7.3 Hz, 1H), 6.75 (d, J = 8.2 Hz, 2H), 4.06 (d, J = 16.0 Hz, 2H), 3.26 (s, 2H), 2.52 (s, 3H), 2.41 (s, 3H), 1.61 (s, 2H), 1.42 (d, J = 16.8 Hz, 4H), 0.97 (t, J = 7.0 Hz, 3H) ppm. [0176] Example 9a-b. cis-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)cyclobutane-1-carboxylic acid (9a) and trans-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)cyclobutane-1-carboxylic acid (9b)

[0177] Step 1. Synthesis of methyl 3-{[3-butyl-2-methyl-7-(methylsulfanyl)-1,1-dioxo- 5-phenyl-3,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl] oxy} cyclobutane-1- carboxylate (9-1). Into a 40 mL vial were added tetrahydrofuran (10 mL), 8-1 (300 mg, 0.73 mmol), methyl 3-hydroxycyclobutane-1-carboxylate (192 mg, 1.47 mmol), triphenylphosphine (387 mg, 1.47 mmol) and DEAD (257 mg, 1.47 mmol) at rt under an atmosphere of N₂. After stirring at rt for 2h, the reaction was quenched by the addition of water/ice (20 mL) at 0°C. The resulting mixture was concentrated, and the residue was extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (2 x 20 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel column chromatography using PE / EA (5/1 (v/v)) as eluent to give 9-1 (240 mg, 63%) as a light brown solid. MS (ESI): calcd. for C₂₆H₃₄N₂O₅S₂: 518; Found: 519 [M+1]⁺. [0178] Step 2. Synthesis of cis-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)cyclobutane-1-carboxylic acid (Example 9a) and trans-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)cyclobutane-1-carboxylic acid (Example 9b). Into a 40 mL vial were added 9-1 (240 mg, 0.46 mmol), dioxane (8 mL), water (2 mL) and LiOH (33 mg, 1.38 mmol) at rt. After stirring at rt for 2 hr, the mixture was acidified to pH 5 with 1 N aq. HCl. The resulting mixture was concentrated, and the residue was extracted with EtOAc (10 mL x2). The combined organic layers were washed with brine (10 mL x 2), dried over anhydrous Na₂SO₄, and concentrated. The crude product was purified by preparative HPLC with the following conditions: Column: XBridge Prep C18 OBD 19*150mm 5um; Mobile Phase A: Water (0.05% HCOOH), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 5% B to 56% B in 8 min; Detecator: UV 220 nm) to give Example 9a (18.5 mg, 16%) as a white solid and Example 9b (4.2 mg, 1.8%) as a white solid. Example 9a: MS (ESI): calcd. for C₁₃H₆F₆N₄O: 504; Found: 505 [M+1]⁺; ¹H NMR (400 MHz, DMSO-d₆): δ 12.32 (s, 1H), 7.17 – 7.13 (m, 2H), 7.06 (d, J = 1.6 Hz, 2H), 6.68 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.0 Hz, 2H), 5.01 – 4.98 (m, 1H), 4.01 (d, J = 16.0 Hz, 1H), 3.88 (s, 1H), 3.18 – 3.09 (m, 2H), 2.68 – 2.63 (m, 2H), 2.44 – 2.38 (m, 8H), 1.64 – 1.57 (m, 1H), 1.50 (s, 1H), 1.35 (s, 4H), 0.95 – 0.87 (m, 3H) ppm. Example 9b: MS (ESI): calcd. for C₂₅H₃₂N₂O₅S₂: 504; Found: 505.2 [M+1]⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.35 (s, 1H), 7.16 – 7.12 (m, 3H), 7.06 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.0 Hz, 2H), 4.85 - 4.81 (m, 2H), 4.00 (d, J = 16.0 Hz, 1H), 3.88 (s, 1H), 3.23 – 3.19 (m, 1H), 2.82 – 2.76 (m, 1H), 2.73 – 2.66 (m, 2H), 2.44 (s, 3H), 2.35 (s, 3H), 2.22 (s, 2H), 1.60 (s, 1H), 1.49 (s, 1H), 1.35 (s, 4H), 0.95 – 0.87 (m, 3H) ppm. [0179] Example 10. (E)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)prop-1-ene-1-sulfonic acid

[0180] Step 1. Synthesis of (1Z)-3-[3-butyl-2-methyl-7-(methylsulfanyl)-1,1-dioxo-5- phenyl-2,3,4,5-tetrahydro-1lambda6,2,5-benzothiadiazepin-8-yl]oxyprop-1-ene-1- sulfonic acid (Example 10). To a solution of 8-1 (60.0 mg, 148 µmol) in DMF (1 mL) was added sodium hydride (5.3 mg, 222 µmol) under an atmosphere of N₂. After stirring at rt for 10 min, the mixture was cooled to -30 °C and 5H-1,2-oxathiole 2,2-dioxide (26.6 mg, 222 µmol) was added. The resulting solution was stirred at rt and quenched by adding 0.1 N aq. HCl (1 mL). The mixture was concentrated, and the residue was purified by preparative HPLC to give Example 10 (38 mg, 46%) as an off-white solid. MS (ESI): calcd. for C₂₃H₃₀N₂O₆S₃: 526; Found: 527 [M+1]⁺; ¹H NMR (400 MHz, DMSO-d₆): δ 7.23 (s, 1H), 7.14 (t, J = 7.8 Hz, 2H), 7.06 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.2 Hz, 2H), 6.25 (dd, J = 11.5, 2.2 Hz, 1H), 5.74 (dt, J = 11.0, 5.2 Hz, 1H), 5.14 (dtd, J = 14.0, 12.1, 3.9 Hz, 2H), 4.01 (d, J = 15.9 Hz, 1H), 3.88 (s, 1H), 3.20 (s, 1H), 2.46 (s, 3H), 2.35 (s, 3H), 1.67 – 1.56 (m, 1H), 1.49 (s, 1H), 1.35 (s, 4H), 0.97 – 0.87 (m, 3H) ppm. [0181] Example 11. (E)-3-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)acrylic acid

[0182] Step 1. Synthesis of ethyl (E)-3-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)acrylate (11-1). Compound 2-7 (100.0 mg, 213 µmol), ethyl (2Z)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2- enoate (192.5 mg, 851 µmol), potassium carbonate (117.65 mg, 851.3 µmol), and [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (17.38 mg, 21.28 µmol) were suspended in degassed dioxane (5 mL). The mixture was heated under argon at 100°C overnight. After cooling to rt, the mixture was diluted with ethyl acetate, the organic layer was washed with water and saturated brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by preparative HPLC to give 11-1 (45 mg, 37%). MS (ESI): calcd. for C₂₅H₃₂N₂O₄S₂: 488; Found: 487 [M-1]-. [0183] Step 2. Synthesis of (E)-3-[3-butyl-2-methyl-7-(methylsulfanyl)-1,1-dioxo-5- phenyl-2,3,4,5-tetrahydro-1lambda6,2,5-benzothiadiazepin-8-yl]prop-2-enoic acid (Example 11). To a stirred solution of 11-1 (45.0 mg, 92 µmol) in a mixture of dioxane and water (3 mL, 2/1 (v/v)), lithium hydroxide (4.4 mg, 184 µmol) was added, and the resulting mixture was stirred at rt overnight. The reaction mixture was treated with 0.1 N aq. HCl (0.1 mL) and then concentrated. The residue was purified by prep HPLC to give Example 11 (19 mg, 45%) as an off-white solid. MS (ESI): calcd. for C₂₃H₂₈N₂O₄S₂: 460, Found: 461 [M+1]⁺; ¹H NMR (400 MHz, DMSO-d6): δ 12.62 (s, 1H), 7.99 (s, 1H), 7.79 (d, J = 15.6 Hz, 1H), 7.25 (t, J = 7.8 Hz, 2H), 7.05 (s, 1H), 6.99 – 6.71 (m, 3H), 6.50 (d, J = 15.6 Hz, 1H), 4.10 (d, J = 15.7 Hz, 1H), 3.74 (s, 1H), 3.47 (s, 1H), 2.58 (s, 3H), 2.39 (s, 3H), 1.56 (s, 2H), 1.34 (s, 4H), 0.91 (d, J = 6.8 Hz, 3H) ppm. [0184] Example 12. (E)-3-(1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropyl)-2-fluoroacrylic acid

[0185] Step 1. Synthesis of 2-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)acetonitrile (12-1). A mixture of 8- bromo-3-butyl-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (2-7) (750.0 mg, 1.63 mmol), 4- (tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazole (635 mg, 3.25 mmol), cesium carbonate (1.59 g, 4.88 mmol) and [1,1'-bis (diphenylphosphino) ferrocene] dichloro palladium(II) dichloromethane adduct (133 mg, 0.16 nnol) in dioxane (5 mL) and water (0.5 mL) was degassed and filled with argon. The mixture was heated to 100 °C overnight, cooled to rt, and diluted with EtOAc (20 mL). The organic phase was washed with water (15 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel flash column chromatography to give 12-1 (150 mg, 22%). MS (ESI): calcd. for C₂₂H₂₇N₃O₂S₂: 429, Found: 430 [M+1]⁺. [0186] Step 2. Synthesis of 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropane-1-carbonitrile (12-2). To a solution of 2-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]-thiadiazepin-8-yl)acetonitrile (12-1) (150.0 mg, 349.16 µmol) in DMF (3 mL) was added sodium hydride (25.12 mg, 1.05 mmol) in few portions at 0°C under an atmosphere of N₂. After gas evolution ceased, 1,2-dibromoethane (65.56 mg, 348.96 µmol) was added dropwise, and the resulting mixture was left to stir overnight at rt. Subsequently, the reaction mixture was diluted with water and EtOAc. The organic layer was separated, washed with brine, dried, and concentrated. The residue was dried in vacuo to give crude 12-2 (150 mg) as a brown solid, which was used in the next step without further purification. MS (ESI): calcd. for C₂₄H₂₉N₃O₂S₂: 455, Found: 456 [M+1]⁺. [0187] Step 3. Synthesis of 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl- 2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropane-1-carbaldehyde (12-3). To a solution of 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropane-1-carbonitrile (12-2) (150 mg, 329.21 µmol) in dry DCM (5 mL) at -78°C was added diisobutylaluminum hydride (43.91 mg, 308.74 µmol, 310.0 µl, 1M in hexane) dropwise, and the reaction mixture was stirred at this temperature for 30 min. The mixture was then allowed to slowly warm up to 0°C and stirring was continued for 2 h. The mixture was quenched by dropwise addition of an aqueous citric solution, and the resulting solution was extracted with DCM (15 mL x 3). The combined organic extracts were washed with water, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative HPLC to give 12-3 (26 mg, 22%) as a yellow oil. MS (ESI): calcd. for C₂₄H₃₀N₂O₃S₂: 458, Found: 459 [M+1]⁺. [0188] Step 4. Synthesis of ethyl (E)-3-(1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido- 5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropyl)-2- fluoroacrylate (12-4). To a solution of ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate (60.2 mg, 248.57 µmol) in THF (5 mL) was added n-butyllithium (248.57 µmol, 100.0 µl, 2.5 M in hexane) at -78°C, and the reaction mixture was allowed to warm up to -20°C. After stirring of the reaction mixture for 30 min at that temperature, it was cooled to -78°C and a solution of 1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropane-1-carbaldehyde (12-3) (38.0 mg, 82.85 µmol) in THF (1 mL) was added dropwise. The resulting mixture was allowed to warm up to rt and stirred overnight. Subsequently, the reaction mixture was quenched with aqueous citric acid and extracted with EtOAc (15 mL x 3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by preparative HPLC to give crude 12-4 (60 mg), which was used in the next step without further purification. MS (ESI): calcd. for C₂₈H₃₅FN₂O₄S₂: 546, Found: 547 [M+1]⁺. [0189] Step 5. Synthesis of (E)-3-(1-(3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropyl)-2-fluoroacrylic acid (Example 12). To a stirred solution of ethyl (E)-3-(1-(3-butyl-2-methyl-7-(methylthio)- 1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)cyclopropyl)-2- fluoroacrylate (12-4) (60 mg, 109.75 µmol) in a mixture of dioxane and water (3 mL, 2:1 (v/v)), lithium hydrate hydroxide (6.08 mg, 144.99 µmol) was added. The resulting mixture was stirred at rt for 12 hr and then added 1 N aq. HCl solution (0.2 mL). The mixture was concentrated, and the residue was purified by preparative HPLC to give Example 12 (10.9 mg, 58%) as a white solid. MS (ESI): calcd. for C₂₆H₃₁FN₂O₄S₂: 518, Found: 519 [M+1]⁺; ¹H NMR (400 MHz, CD₃CN): δ 8.11 (s, 1H), 7.22 (dd, J = 8.8, 7.2 Hz, 2H), 7.08 (s, 1H), 6.80 (t, J = 7.3 Hz, 1H), 6.70 (d, J = 8.1 Hz, 2H), 6.46 (d, J = 21.7 Hz, 1H), 4.02 (d, J = 16.3 Hz, 2H), 3.28 (s, 1H), 2.51 (s, 3H), 2.42 (d, J = 2.4 Hz, 3H), 1.66 – 1.54 (m, 2H), 1.43 (tq, J = 14.2, 7.3 Hz, 4H), 1.24 (dd, J = 12.0, 3.0 Hz, 4H), 0.97 (t, J = 6.9 Hz, 3H) ppm. [0190] Table 1 shows structures and analytical data for representative Examples of the present invention. These compounds can be prepared according to the synthetic schemes described above and using procedures known to those of ordinary skill in the art. Table 1: Representative Examples of the present invention

V. Biological Data [0191] HepG2-NTCP infection protocol [0192] HepG2 cells expressing the sodium taurocholate cotransporting polypeptide (HepG2-NTCP) were maintained in culture using HepG2-NTCP growth medium (DMEM (HyClone, Cat# SH30243.02) supplemented with 10% FBS, 150 µg/mL G418 (Alfa Aesar, Cat# J62671), 50U/mL penicillin-streptomycin (Invitrogen, Cat# 15140-122), and 0.5 µg/mL blasticidin (Sigma, Cat# 15205)). Prior to infection, the cells were washed twice with 1× DPBS (Invitrogen, Cat# 14190-136) and treated with 3 mL of 0.05% trypsin (Invitrogen, Cat# 25200-056) to dissociate the cells. Following dissociation, 10 mL of HepG2-NTCP growth medium was added to the cells to neutralize the trypsin and the cells were then centrifuged at 1,300 rpm for 5 minutes. Following centrifugation, the cells were resuspended in 10 mL of HepG2-NTCP growth medium, counted, and then centrifuged at 1,300 rpm for 5 minutes. The cell pellet was resuspended in DMEM supplemented with 5% FBS, 50U/mL penicillin-streptomycin, 4% PEG-8000 (Hamilton Research, Cat# HR2-515), and 1% DMSO (Sigma, Cat# D4540) to a density of 5.6 × 10⁵ cells/mL and infected with HBV at an MOI of 50. Immediately after infection, 90 µL of the cell/HBV mixture was added to a 96-well plate containing 10 µL of compound and incubated at 37⁰C for 24 hours (2% final DMSO concentration). After the incubation, the infection media was removed and replaced with DMEM supplemented with 5% FBS, 50U/mL penicillin-streptomycin, and 1% DMSO and incubated for an additional 72 hours. At the end of the incubation, the plates were spun at 1,800 rpm for 8 minutes and the supernatant was removed for HBeAg quantification using electrochemiluminescence enzyme-linked immunosorbent assays (ECL-ELISA). [0193] To conduct the HBeAg ECL-ELISA, Lumitrack high-binding 96-well plates (Greiner, Cat# 655074) were treated with 625 ng/mL HBeAg mAb (Biocheck, Cat# 70426) in 1× DPBS for 2 hours at 25⁰C with shaking. The HBeAg mAb solution was then removed and the plates treated with 1× DPBS containing 0.5% bovine serum albumin (BSA) (Sigma, Cat# A7030-100g) for 2 hours at 25⁰C with shaking. The HBeAg-coated plates were then washed 4 times with 1× DPBS containing 0.05% Tween 20 (DPBS-T) (Thermo Fisher Scientific, Cat# J61544-K2). Following the wash, 90 µL of HRP-conjugated antibody (Fitzgerald, Cat# 61-H10K), diluted 1:8,000 in 1× DPBS-T containing 0.5% BSA, was added to the HBeAg-coated plates along with 10 µL of sample. The plates were then incubated for 2 hours at 25 ⁰C with shaking. Following the incubation, the sample was then removed and 200 µL of 1× PBS-T was added and the plates were incubated for 10 minutes at 25⁰C with shaking. The plates were then washed 6 times with 1× PBS-T and blotted dry.80 µL of ECL substrate (Millipore, Cat# WBKLS0500) was then added to the plate and the luminescence was measured using a Tecan M1000 Pro plate reader. [0194] Other assays are known in the art, see for example, Lempp et al., Nature Communications, 2019, 10:2265, https://doi.org/10.1038/s41467-019-10211-2, Grosser et al., Frontiers in Molecular Biosciences, 2021, 8: doi: 10.3389/fmolb.2021.689757. [0195] Table 2 provides assay data for exemplified compounds of the invention grouped in the following ranges: A indicates EC₅₀ < 100 nM; B indicates EC₅₀ of ≥100 to <1,000 nM; C indicates EC₅₀ of ≥1,000 to <5,000 nM. Table 2. Assay data for exemplified compounds of the invention.

INCORPORATION BY REFERENCE [0196] All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. EQUIVALENTS [0197] While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations. [0198] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure.

Claims

CLAIMS: 1. A compound of Formula II

Formula II , or a pharmaceutically acceptable salt thereof, wherein: M is NR^x or CR²R³; R^x is hydrogen or C_1-4alkyl; and R⁰ is -C(O)OH, -C(O)OC_1-4alkyl, or -S(O)₂OH; R¹ is phenyl or monocyclo_5-6heteroaryl, wherein the phenyl or monocyclo_5-6heteroaryl is substituted with R⁰ and optionally substituted with 1-3 substituents independently selected from the group consisting of cyano, halo, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_{1- 4}alkylthio; R² and R³ are independently selected from the group consisting of hydrogen, halo and methyl. R⁴ is independently selected from the group consisting of hydrogen, halo, cyano, C_{1- 4}alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio; and R⁵ is phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy, and C_1-4alkylthio.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein M is NR^x.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein M is NH or NCH₃.

4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R⁰ is -C(O)OH or -C(O)OC_1-4alkyl.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R⁰ is -C(O)OH.

6. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R¹ is phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio.

7. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R¹ is monocyclo_5-6heteroaryl optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R¹ is

R⁶ is independently selected for each occurrence from the group consisting of halo, OH, CN, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy and C_1-4alkylthio; R^6a is hydrogen or C_1-6alkyl; X is O or S; v is 0, 1, 2 or 3; w is 0, 1 or 2; and u is 0 or 1.

9. The compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R⁴ is fluoro, methyl or methylthio.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R⁴ is methylthio.

11. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R⁵ is

12. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

13. A pharmaceutical composition comprising a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

14. A method of treating Hepatitis B (HBV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof.

15. A method of treating Hepatitis B (HBV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 13.

16. A method of treating Hepatitis D (HDV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof.

17. A method of treating Hepatitis D (HDV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 13.